Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $2.19 billion. The enterprise value is $2.71 billion.
Important Dates
The last earnings date was Thursday, February 12, 2026, after market close.
| Earnings Date | Feb 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RARE has 96.43 million shares outstanding. The number of shares has increased by 8.90% in one year.
| Current Share Class | 96.43M |
| Shares Outstanding | 96.43M |
| Shares Change (YoY) | +8.90% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 3.49% |
| Owned by Institutions (%) | 96.84% |
| Float | 93.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.26 |
| Forward PS | 2.74 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.02 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.48
| Current Ratio | 2.48 |
| Quick Ratio | 2.19 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.63 |
Financial Efficiency
Return on equity (ROE) is -608.47% and return on invested capital (ROIC) is -28.45%.
| Return on Equity (ROE) | -608.47% |
| Return on Assets (ROA) | -22.03% |
| Return on Invested Capital (ROIC) | -28.45% |
| Return on Capital Employed (ROCE) | -46.60% |
| Weighted Average Cost of Capital (WACC) | 4.67% |
| Revenue Per Employee | $520,093 |
| Profits Per Employee | -$444,359 |
| Employee Count | 1,294 |
| Asset Turnover | 0.44 |
| Inventory Turnover | 17.71 |
Taxes
In the past 12 months, RARE has paid $4.00 million in taxes.
| Income Tax | 4.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.70% in the last 52 weeks. The beta is 0.16, so RARE's price volatility has been lower than the market average.
| Beta (5Y) | 0.16 |
| 52-Week Price Change | -48.70% |
| 50-Day Moving Average | 26.29 |
| 200-Day Moving Average | 30.98 |
| Relative Strength Index (RSI) | 44.83 |
| Average Volume (20 Days) | 2,488,759 |
Short Selling Information
The latest short interest is 9.10 million, so 9.43% of the outstanding shares have been sold short.
| Short Interest | 9.10M |
| Short Previous Month | 8.86M |
| Short % of Shares Out | 9.43% |
| Short % of Float | 9.78% |
| Short Ratio (days to cover) | 2.77 |
Income Statement
In the last 12 months, RARE had revenue of $673.00 million and -$575.00 million in losses.
| Revenue | 673.00M |
| Gross Profit | -186.00M |
| Operating Income | -535.00M |
| Pretax Income | -571.00M |
| Net Income | -575.00M |
| EBITDA | -500.00M |
| EBIT | -535.00M |
| Earnings Per Share (EPS) | n/a |
Full Income StatementBalance Sheet
The company has $680.00 million in cash and $1.25 billion in debt, with a net cash position of -$515.00 million or -$5.34 per share.
| Cash & Cash Equivalents | 680.00M |
| Total Debt | 1.25B |
| Net Cash | -515.00M |
| Net Cash Per Share | -$5.34 |
| Equity (Book Value) | -73.00M |
| Book Value Per Share | -0.83 |
| Working Capital | 567.00M |
Full Balance SheetCash Flow
| Operating Cash Flow | -466.00M |
| Capital Expenditures | -6.00M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is -27.64%, with operating and profit margins of -79.49% and -85.44%.
| Gross Margin | -27.64% |
| Operating Margin | -79.49% |
| Pretax Margin | -84.84% |
| Profit Margin | -85.44% |
| EBITDA Margin | -74.29% |
| EBIT Margin | -79.49% |
| FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.90% |
| Shareholder Yield | -8.90% |
| Earnings Yield | -26.25% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RARE is $66.32, which is 191.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $66.32 |
| Price Target Difference | 191.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 30.42% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -3.17 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.17 |
| Piotroski F-Score | 4 |
